Actively Recruiting
Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity
Led by National Cancer Institute, Egypt · Updated on 2025-12-11
58
Participants Needed
1
Research Sites
23 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.
CONDITIONS
Official Title
Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 60 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status of II-III.
- Height between 150-185 cm.
- Body mass index between 18-35 kg/m8.
- Scheduled for above-knee amputation due to lower limb sarcomas.
You will not qualify if you...
- Allergy to any of the investigated drugs.
- History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel-blockers, or angiotensin-converting-enzyme inhibitors.
- Contraindications to spinal anesthesia.
- Pregnancy or lactation.
- Presence of psychiatric illness or chronic pain conditions.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Institute
Cairo, Egypt, 11796
Actively Recruiting
Research Team
M
Mai M Elrawas, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here